Target type: molecularfunction
Enables the transmembrane transfer of a potassium ion by an inwardly-rectifying voltage-gated channel, where the inward rectification is due to a voltage-dependent block of the channel pore by ATP. An inwardly rectifying current-voltage relation is one where at any given driving force the inward flow of K+ ions exceeds the outward flow for the opposite driving force. [GOC:cb, GOC:mah]
ATP-activated inward rectifier potassium channels (Kir channels) are a family of ion channels responsible for regulating potassium ion (K+) permeability across cell membranes. Their unique characteristic lies in their sensitivity to intracellular ATP, which acts as a direct regulator of channel activity.
When intracellular ATP levels are high, these channels are inhibited, preventing K+ efflux from the cell. Conversely, when ATP levels drop, the channels open, allowing K+ to flow out of the cell. This mechanism plays a crucial role in maintaining cellular homeostasis, particularly in response to energy stress.
The molecular mechanism of ATP-activated inward rectifier potassium channel activity involves a complex interplay of structural elements and their interactions with ATP.
The channel's structure consists of four transmembrane domains, which form a pore through the membrane. The pore is lined with amino acid residues that interact with K+ ions, allowing them to pass through the channel.
The ATP-binding site is located within the intracellular domain of the channel. This site is highly conserved across different Kir channel subtypes and is responsible for ATP's regulatory action.
When ATP binds to this site, it triggers a conformational change in the channel protein, leading to closure of the pore and inhibition of K+ permeability. This conformational change is thought to involve a direct interaction between ATP and the channel's cytosolic domain.
The specific mechanism by which ATP binding leads to channel closure remains an area of active research. However, studies have shown that ATP binding induces a change in the channel's gating properties, leading to a shift in the equilibrium between open and closed states. This shift favors the closed state, resulting in reduced K+ permeability.
The precise molecular events leading to this shift are still under investigation, but they are likely to involve a combination of factors, including:
- Direct interactions between ATP and specific amino acid residues within the ATP-binding site
- Conformational changes within the channel protein that propagate from the ATP-binding site to the pore region
- Changes in the interactions between the channel protein and other cellular components
The ATP sensitivity of Kir channels plays a critical role in regulating cellular function in various tissues and organs. For example, in the heart, these channels contribute to maintaining the resting membrane potential and regulating heart rate. In the brain, they are involved in neurotransmission and neuronal excitability. In the pancreas, they help regulate insulin secretion.
In addition to their role in normal cellular function, Kir channels are also implicated in various pathological conditions, including diabetes, heart disease, and neurological disorders.
Therefore, understanding the molecular mechanism of ATP-activated inward rectifier potassium channel activity is essential for developing new therapeutic strategies targeting these channels in various diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
ATP-binding cassette sub-family C member 8 | An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428] | Homo sapiens (human) |
ATP-sensitive inward rectifier potassium channel 1 | An ATP-sensitive inward rectifier potassium channel 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P48048] | Homo sapiens (human) |
ATP-sensitive inward rectifier potassium channel 8 | An ATP-sensitive inward rectifier potassium channel 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q15842] | Homo sapiens (human) |
ATP-sensitive inward rectifier potassium channel 11 | An ATP-sensitive inward rectifier potassium channel 11 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q14654] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 8 | An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 8 | An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 9 | An ATP-binding cassette sub-family C member 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60706] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
diazoxide | diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
pinacidil | Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) | pyridines | |
propafenone | propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
troglitazone | Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. | chromanes; thiazolidinone | anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent |
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine | N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener | pyridines | |
repaglinide | piperidines | ||
cromakalim | Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352) | ||
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
mk 767 | 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source | ||
zeneca zd 6169 | Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source | ||
cromakalim | 1-benzopyran | ||
clamikalant | clamikalant: inhibits ATP-sensitive potassium channel; structure in first source | ||
7,13-bis(4-nitrobenzyl)-1,4,10-trioxa-7,13-diazacyclopentadecane | 7,13-bis(4-nitrobenzyl)-1,4,10-trioxa-7,13-diazacyclopentadecane: Potassium channel blocker; structure in first source | ||
zm226600 | ZM226600: an ATP-sensitive potassium channel opener; structure in first source | anilide | |
way 133537 | |||
ly 465608 | LY 465608: a nonthiazolidinedione agonist of both PPAR-alpha and PPAR-gamma of Ligand Pharm. and Eli Lilly | ||
bm 131246 | |||
nn 414 | NN 414: a hypoglycemic agent with insulin release modulating and potassium channel activating activities; structure in first source | ||
7-chloro-3-isopropylamino-4h-1,2,4-benzothiadiazine 1,1-dioxide | 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide: activates ATP-sensitive potassium channels; structure in first source |